Growing Market Focus SIGA Technologies concentrates on developing treatments for highly infectious and emerging diseases such as smallpox, mpox, and orthopoxviruses, positioning it as a key player in pandemic preparedness and biothreat defense markets.

Strategic Partnerships Recent collaborations with Vanderbilt University, Calidi Biotherapeutics, and Meridian Medical Ltd. highlight opportunities to expand product pipelines and licensing agreements, opening doors for joint ventures and licensing deals with health-focused organizations.

Robust Funding & Revenue With revenue exceeding 100 million dollars and recent funding of 23 million dollars, SIGA has the financial capacity to accelerate product development and scale manufacturing, presenting opportunities for investors or supply chain partners.

Government & Defense Ties Active collaboration with the Department of Defense on Post-exposure Prophylaxis development and related government contracts underscore potential sales pathways within military, federal health agencies, and emergency response sectors.

Innovative Product Development SIGA's focus on next-generation treatments such as monoclonal antibodies and broad-spectrum antivirals offers opportunities to sell complementary medical products, diagnostics, or support services to healthcare providers and research institutions.